Drug reference
enoximone
Phosphodiesterase inhibitor · Positive inotropic agent, Vasodilator, Agent for acute heart failure
Phosphodiesterase inhibitorPositive inotropic agent, Vasodilator, Agent for acute heart failure
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
—
none in our sources
PREGNANCY
—
not curated
Mechanism
Not yet extracted
Indications
short-term circulation support in advanced CHF
Dosing
- Adult
- Bolus doses of 0.5 to 1.0 mg/kg over 5 to 10 min, followed by an infusion of 5 to 20 μg/kg/min.
Pharmacokinetics
Half-life
2 to 3 hours (normal individuals)
Contraindications
- systolic pressure less than 85 mm Hg
Side effects
Common
hypotension
Serious
- tachycardic and arrhythmogenic effects
- increased cardiac energy consumption and risk of arrhythmia
Related guidelines
Ask House about enoximone
Continue into a citation-backed clinical answer with the drug context already attached.
Textbook-sourced·Sources: Goodman & Gilman 14e·Updated: 2026-05-10